The U.S. Food and Drug Administration has agreed to review Otsuka Pharmaceutical’s application for centanafadine, a new extended‑release therapy under investigation for attention‑deficit hyperactivity disorder (ADHD). The agency has granted priority review, signaling that the treatment may address an unmet medical need. A final decision is expected by July 24, 2026 under the Prescription Drug User Fee Act timeline.
If approved, centanafadine would represent the first medication in a new class of norepinephrine, dopamine, and serotonin reuptake inhibitors (NDSRIs) for ADHD, offering a mechanism of action distinct from existing stimulant and non‑stimulant therapies.
A New Pharmacologic Class for ADHD Management
Centanafadine is designed as a once‑daily, extended‑release capsule intended to influence three key neurotransmitter systems implicated in ADHD. By modulating norepinephrine, dopamine, and serotonin pathways simultaneously, the therapy aims to address a wide range of symptoms.
John Kraus, M.D., Ph.D., chief medical officer at Otsuka Pharmaceutical Development & Commercialization, stated that the priority review marks a major step toward broadening the therapeutic landscape for patients, emphasizing the importance of additional treatment approaches for a condition that presents differently across individuals.
Phase 3 Clinical Evidence
Otsuka’s NDA submission is based on four late‑stage clinical trials that assessed the medication in children, adolescents, and adults. Across these studies:
- Pediatric participants demonstrated improvements on the ADHD Rating Scale‑5 (ADHD‑RS‑5).
- Adults showed significant symptom reduction on the ADHD Investigator Symptom Rating Scale (AISRS).
The investigational therapy was generally well tolerated.
Most frequently reported side effects included:
- Children & adolescents: decreased appetite, fatigue, abdominal discomfort, rash, nausea, and increased sleepiness
- Adults: decreased appetite and headache
Preclinical and clinical findings also indicate a low likelihood of misuse or abuse, according to Otsuka.
ADHD’s Prevalence and Unmet Need
ADHD is a long‑term neurodevelopmental condition characterized by challenges with attention, impulsivity, and hyperactivity. While it is commonly identified during childhood, symptoms can persist throughout adulthood and may significantly affect daily functioning.
Current estimates indicate:
- Approximately 7 million children in the United States have been diagnosed
- An estimated 15.5 million adults are currently living with the disorder
The sustained prevalence in adulthood underscores the need for therapies that address symptoms across all age brackets.
Looking Ahead
The priority review puts centanafadine on track for a regulatory decision in mid‑2026. Should the FDA grant approval, it would introduce a novel, first‑in‑class NDSRI treatment option for individuals with ADHD, potentially expanding clinicians’ ability to tailor therapy to diverse patient needs.
